$Halozyme Therapeutics (HALO.US)$Revenue plummeted by half t...
$Halozyme Therapeutics(HALO.US$Revenue plummeted by half to 150 million in 2018, then grew rapidly to 440 million in the following three years. Operating profit reversed losses to 140 million in 2020, reached 280 million in 2021, net profit reached 130 million in 2020, and 400 million in 2021.
Revenue increased 40% to 480 million dollars in the first three quarters of 2022, but due to the sharp increase in expenses, operating profit fell 12%, and net profit fell 57% to 144 million.
Currently, the price-earnings ratio is 18.4, and the price-earnings ratio TTM has reached 34. It seems that the results for the whole year will not be very good, and it is currently unattractive.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
